Effects of agomelatine on heart rate variability in patients with coronary artery disease and depression

Aim. To determine heart rate variability (HRV) in depressed patients with chronic coronary artery disease (CAD) and to assess the effects of agomelatine on HRV.
Methods. 74 patients with CAD (class 3-4 angina pectoris) were recruited in a study. Patients (n = 45) with CAD and depression were assigned to Group 1, whereas CAD patients (n = 29) without any signs of depression were assigned to Group 2. 17 patients received agomelatine (Subgroup 1) and 28 patients did not take any antidepressants (Subgroup 2). HRV was measured using SCHILLER MT-200 Holter-ECG apparatus at baseline and after 6 months.
Results. Patients with depression demonstrated a significant decrease in HRV compared to non-depressed patients (pNN50% (3.9 [2.2; 5.4] vs 5.7 [2.9; 12.6], p = 0.03), SDANN (81 [63; 97] ms vs 91 [79; 102] ms, p = 0.06), SDNNindx (46 [36; 56] ms vs 55 [48; 66] ms, p = 0.002), rMSSD (28 [21; 36] ms vs 33 [ 29; 45] ms, p = 0.02), SDNN (97 [75; 121] ms vs 110 [98; 127] ms, p = 0.02). Subgroups 1 and 2 did not differ in HRV (p>0.05). After 6 months, significant differences in the following parameters were found in those patients who received agomelatine therapy and those who did not: rMSSD (36.5 [28.5; 51] ms vs 26.5 [25; 32] ms, p = 0.02), SDANN (88 [72,5; 114,5] ms vs 67,5 [58; 83] ms, p = 0.03), SDNN strives to a significant difference - 100 [87; 133.5] ms vs 85.5 [75; 103] ms, p = 0.07.
Conclusion. HRV significantly decreased in depressed patients with CAD suggesting autonomic dysfunction and worsening their prognosis. Agomelatine therapy in patients with CAD is effective in treating heart rate variability and reducing the risk of developing life-threatening arrhythmias.
Key

1. Khandaker G.M., Zuber V., Rees J.M.B., Carvalho L., Mason A.M., Foley C.N., Gkatzionis A., Jones P.B., Burgess S. Shared mechanisms between coronary heart disease and depression: findings from a large UK general populationbased cohort. Molecular Psychiatry 2020; 25(7):1477-1486. doi:10.1038/s41380-019-0395-3.

2. Pogosova G.V. Depression - a Risk Factor for Coronary Heart Disease and a Predictor of Coronary Death: 10 Years of Scientific Research. Cardiology. 2012; 52 (12): 4-11. (In Russian)

3. Nonka T.G. The clinical course of coronary heart disease, heart rate variability, structural changes in the brain in patients with myocardial infarction in combination with depression [dissertation]. Tomsk: State Institution "Research Institute of Cardiology of the Scientific Center of the Siberian Branch of the Russian Academy of Medical Sciences"; 2011g. (In Russian)

4. Lebedeva E.V., Nonka T.G., Repin A.N. SHishneva E.V., Schastnyj E.D., Simutkin G.G., Levchuk L.A.Modern psychocardiology. Tomsk: Publishing house LLC Integral binding; 2019. 160 p. (In Russian) ISBN: 978-5-6041467-1-2.

5. WHO. News bulletin. Depression. Let's talk. Electronic scientific journal. "Social aspects of population health". 2017; 54 (2). (In Russian)

6. Khandaker G.M., Zuber V., Rees J.M.B., Carvalho L., Mason A.M., Foley C.N., Gkatzionis A., Jones P.B., Burgess S. Shared mechanisms between coronary heart disease and depression: findings from a large UK general population-based cohort. Molecular Psychiatry; 2020; 25 (7): 1477-1486. doi: 10.1038/s41380-019-0395-3.

7. Patel H., Mazur W., Williams K.A. Sr, Kalra D.K. Myocardial viability-State of the art: Is it still relevant and how to best assess it with imaging? Trends Cardiovasc Med. 2018; 28 (1): 24-37. doi:10.1016/j.tcm.2017.07.001.

8. Pushkarev G.S., Kuznetsov V.A., Fisher Y.A., Soldatova A.M., Sapozhnikova A.D., Enina T.N. Effect of depressive symptoms on the risk of death from all causes in patients with chronic heart failure who underwent cardiac resynchronization therapy. Cardiology. 2019; 59 (1): 5-11. (In Russian) doi:10.18087/cardio.2019.1.10211.

9. Kornetov N.A., Lebedeva E.V. Depressive disorders in patients after myocardial infarction. Psychiatry and psychopharmacotherapy. 2003; 5: 195-198. (In Russian)

10. Smulevich A.B. Depression in mental and somatic disease. 4nd ed. Moscow: Medical Information Agency; 2015. 640 p. (In Russian) ISBN: 978-5-9986-0221-4.

11. Lebedeva E.V., Schastny E.D., Simutkin G.G., Repin A.N., Nonka T.G. Clinical characteristics of affective disorders and the effectiveness of antidepressant therapy in patients with chronic coronary heart disease. Bulletin of Siberian medicine. 2018; 17 (4): 85-93. (In Russian) doi:10.20538/1682-0363-2018-4-85-93.

12. Spurgeon L., James G., Sackley C. The Hospital Anxiety and Depression Scale: a pilot study to examine its latent structure and the link between psychological state and symptom severity in transient ischaemic attack patients. Psychol Health Med. 2016; 21 (5): 632-8. doi: 10.1080/13548506.2015.1074711.

13. Arat S., de Cock D., Moons P., Vandenberghe J., Westhovens R. Modifiable correlates of illness perceptions in adults with chronic somatic con-ditions: A systematic review. Res Nurs Health. 2018; 41 (2): 173-84. doi:10.1002/nur.21852.

14. Palacios .J, Khondoker M., Mann A., Tylee A., Hotopf M. Depression and anxiety symptom trajectories in coronary heart disease: Associa-tions with measures of disability and impact on 3-year health care costs. J Psychosom Res. 2018; 104: 1-8. doi: 10.1016/j.jpsychores.2017.10.015.

15. Drobyzhev M.Yu., Serdyuk O.V., Ovchinnikov A.A., Kikta S.V., Retyunsky K.Yu. Pathogenetic and pharmacological approach when choosing antidepressants. Social and clinical psychiatry. 2014; 24 (2): 86-91. (In Russian)

16. Drobizhev M. Yu., Ovchinnikov A. A, Kikta S. V. Mechanisms of action of antidepressants and the pathogenesis of mental disorders. What are the matches? Social and clinical psychiatry. 2017; 27 (3): 94-101. (In Russian)

17. Statsenko M. E., Tyshenko I. A. Pathogenesis and treatment options for comorbid depression in patients with coronary heart disease: a view of a cardiologist. Medicinal Bulletin. 2018; 12 (1): 28-34. (In Russian)

18. Ushkalova E.A., Ushkalova A.V. Pharmacotherapy for depression in cardiac patients. Difficult patient. 2006; 1: 51-57. (In Russian)

19. Baranov A.P., Strutinsky A.V., Oinotkinova O.Sh., Baranova A.A., Trishina V.V., Golubev Yu.Yu., Kruzhalov A.N. Treatment options for anxiety and depressive disorders in patients with chronic heart failure. Russian Journal of Cardiology. 2017; 22 (1): 128-135. (In Russian) doi:10.15829/1560-4071-2017-1-128-135.

20. Medvedev V.E. Prospects for the use of melatonergic drugs in the treatment of depression in patients with cardiovascular disease. Psychiatry and psychopharmacotherapy them. P. B. Gannushkina. 2010; 03: 17-22. (In Russian)

21. Shimohina N.Y., Petrova M.M., Savchenko A.A., Chernyaeva M.S. Agomelatine in the treatment of anxiety and depressive disorders in patients with ischemic heart disease. Rational Pharmacotherapy in Cardiology. 2017; 13 (1): 116-123. (In Russian) doi.10.20996/1819-6446-2017-13-1-116-123

22. Gayfullina R., Kim Z., Streltsova L., Mustafina E., Khayatova Z., Pavlova M. Valdoxan in the complex treatment of patients with coronary artery disease. Doctor. 2012; 9: 78-82 (In Russian)

23. Mikhailovich A.I., Yanushko P.S. Possibilities of using agomelatine in the treatment of anxiety-depressive disorders in patients with unstable angina pectoris. Bulletin of medical Internet conferences. 2014; 4 (4). (In Russian) ISSN 2224-6150

24. Statsenko M.E., Shilina N.N., Turkina S.V. The efficiency of Valdoxan use in the rehabilitation period after myocardial infarction in patients with type 2 diabetes mellitus and anxiety-depressive disorders. Psychiatry and psychopharmacotherapy them. P. B. Gannushkina. 2012; 6: 8-13. (In Russian)

25. Poponina T.M., Gunderina K.I., Poponina Y.S., Soldatenko M.V. The effect of agomelatine on heart rate variability in patients with anxiety-depressive disorders who suffered acute coronary syndrome. The Siberian Medical Journal. 2018; 33 (3): 36-45. (In Russian) doi: 10.29001/20738552-2018-33-3-36-45

26. Bigger J.T., Fleiss J.L., Steinman R.C., Rolnitzky L.M., Schneider W.J., Stein P.K. RR variability in healthy, middle-aged persons compared with patients with chronic coronary heart disease or recent acute myocardial infarction. Circulation. 1995. Vol. 7. P. 1936-1943. doi: 10.1161/01.cir.91.7.1936.

27. Sumin A.N., Shushunova O.V., Arhipov O.G. Autonomic nervous system adaptations in patients with arterial hypertension and their correlations with clinical and echocardiographic parameters. Complex Issues of Cardiovascular Diseases. 2017; 6 (4): 6-13. (In Russian) doi.org/10.17802/2306-1278-2017-6-4-6-13

28. Taylor C.B., Youngblood M.E., Catellier D., Veith R.C., Carney R.M., Burg M.M., Kaufmann P.G., Shuster J., Mellman T., Blumenthal J.A., Krishnan R., Jaffe A.S.; ENRICHD Investigators. Effects of Antidepressant Medication on Morbidity and Mortality in Depressed Patients After Myocardial Infarction. ENRICHD trial Arch. Gen. Psychiatry. 2005; 62: 792-798. doi: 10.1001/archpsyc.62.7.792.

29. Trofimova O.V., Tochilov V.A., Baldueva S.A. Paxil (paroxetine) treatment for anxious depression in patients with an early post-infarction period. Attending doctor. 2003; 7: 7678. (In Russian)

30. Pomeshkina S. A., Bezzubova V.A., Solodukhin A. V., Sery A. V., Ardashova N. Yu. Linkages between Compliance and Mental Status in Patients after Coronary Artery Bypass Graft Surgery. Doctor. Ru. 2017; 5 (134): 36-41. (In Russian)